Previous 10 | Next 10 |
Prof. June is a world authority on immune tolerance and adoptive immunotherapy Appointment re affirm s AC Immune’s scien tific leadership in neurodegeneration LAUSANNE, Switzerland, Nov. 20, 2020 (GLOBE NEWSWIRE) -- AC Immune ...
Prof. Streffer is a n established authority on n euroscience and b iomarker modalities Appointment re affirm s AC Immune’s scien tific leadership in neurodegeneration LAUSANNE, Switzerland, ...
AC Immune (ACIU): Q3 Non-GAAP EPS of -CHF0.24 misses by CHF0.02; GAAP EPS of -CHF0.26 misses by CHF0.01.Revenue of CHF1.12M (-96.6% Y/Y) beats by CHF0.55M.Press Release For further details see: AC Immune EPS misses by CHF0.02, beats on revenue
Phase 1 trial completed in Lilly Morphomer™ Tau partnership program with plans to evaluate candidates in Alzheimer’s disease and NeuroOrphan indications First-in-class TDP-43 therapeutic and diagnostic programs advance as the target’s role in a newly defined form ...
LAUSANNE, Switzerland, Nov. 12, 2020 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced that it will participate in a fireside chat during the upcoming Jefferie...
AC Immune (ACIU) and WuXi Biologics (WXXWY) plan to accelerate advancement of AC Immune’s TDP-43 antibody into clinical development for NeuroOrphan indications. This next phase of the strategic partnership between the companies builds on the know-how of ACIU's drug discovery and develo...
LAUSANNE, Switzerland, Nov. 09, 2020 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases and WuXi Biologics (“WuXi Bio”) (2269.HK), a global company with leading op...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
AC Immune suffers setback on Alzheimer’s front. Galera Therapeutics provides positive update of GC4419 in pancreatic cancer. Forma Therapeutics reports positive topline data from Phase 2 Olutasidenib trial. For further details see: AC Immune's Alzheimer's Setback,...
Grant from the ‘ EU Joint Programme – Neurodegenerative Disease Research ’ (JPND) provides €1.45M in funding for the program AC Immune’s proprietary Morphomer™ platform continues accele...
News, Short Squeeze, Breakout and More Instantly...
AC Immune Showcasing its Novel Morphomer-Antibody Drug Conjugate (morADC) Platform for the Treatment of Neurodegenerative Diseases at AAIC 2024 Three oral presentations at the Alzheimer’s Association International Conference (AAIC 2024), including talks on morADC, ACI-24.060,...
2024-05-30 18:30:02 ET BTIG analyst issues BUY recommendation for ACIU on May 30, 2024 04:49PM ET. ACIU was trading at $3.97 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 1 - Buy recommendations . ...
2024-05-30 18:00:07 ET Thomas Shrader from BTIG issued a price target of $8.00 for ACIU on 2024-05-30 16:49:00. The adjusted price target was set to $8.00. At the time of the announcement, ACIU was trading at $3.97. The overall price target consensus is at $10.00 with hi...